CDXS
Price
$2.30
Change
-$0.05 (-2.13%)
Updated
May 30 closing price
Capitalization
190.54M
60 days until earnings call
CSLLY
Price
$79.76
Change
-$0.01 (-0.01%)
Updated
May 30 closing price
Capitalization
76.83B
Interact to see
Advertisement

CDXS vs CSLLY

Header iconCDXS vs CSLLY Comparison
Open Charts CDXS vs CSLLYBanner chart's image
Codexis
Price$2.30
Change-$0.05 (-2.13%)
Volume$870.67K
Capitalization190.54M
CSL
Price$79.76
Change-$0.01 (-0.01%)
Volume$59.72K
Capitalization76.83B
CDXS vs CSLLY Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. CSLLY commentary
Jun 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and CSLLY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 01, 2025
Stock price -- (CDXS: $2.30 vs. CSLLY: $79.76)
Brand notoriety: CDXS and CSLLY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 95% vs. CSLLY: 61%
Market capitalization -- CDXS: $190.54M vs. CSLLY: $76.83B
CDXS [@Biotechnology] is valued at $190.54M. CSLLY’s [@Biotechnology] market capitalization is $76.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $303.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileCSLLY’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • CSLLY’s FA Score: 1 green, 4 red.
According to our system of comparison, CSLLY is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 2 TA indicator(s) are bullish while CSLLY’s TA Score has 6 bullish TA indicator(s).

  • CDXS’s TA Score: 2 bullish, 7 bearish.
  • CSLLY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CSLLY is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а -4.17% price change this week, while CSLLY (@Biotechnology) price change was +0.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSLLY($76.8B) has a higher market cap than CDXS($191M). CSLLY YTD gains are higher at: -8.156 vs. CDXS (-51.782). CSLLY has higher annual earnings (EBITDA): 4.73B vs. CDXS (-53.41M). CSLLY has more cash in the bank: 1.52B vs. CDXS (73.5M). CDXS has less debt than CSLLY: CDXS (59.9M) vs CSLLY (12B). CSLLY has higher revenues than CDXS: CSLLY (14.7B) vs CDXS (59.3M).
CDXSCSLLYCDXS / CSLLY
Capitalization191M76.8B0%
EBITDA-53.41M4.73B-1%
Gain YTD-51.782-8.156635%
P/E RatioN/A29.27-
Revenue59.3M14.7B0%
Total Cash73.5M1.52B5%
Total Debt59.9M12B0%
FUNDAMENTALS RATINGS
CDXS vs CSLLY: Fundamental Ratings
CDXS
CSLLY
OUTLOOK RATING
1..100
4250
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9553
PRICE GROWTH RATING
1..100
8574
P/E GROWTH RATING
1..100
10075
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CSLLY's Valuation (2) in the null industry is somewhat better than the same rating for CDXS (45) in the Chemicals Specialty industry. This means that CSLLY’s stock grew somewhat faster than CDXS’s over the last 12 months.

CSLLY's Profit vs Risk Rating (100) in the null industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that CSLLY’s stock grew similarly to CDXS’s over the last 12 months.

CSLLY's SMR Rating (53) in the null industry is somewhat better than the same rating for CDXS (95) in the Chemicals Specialty industry. This means that CSLLY’s stock grew somewhat faster than CDXS’s over the last 12 months.

CSLLY's Price Growth Rating (74) in the null industry is in the same range as CDXS (85) in the Chemicals Specialty industry. This means that CSLLY’s stock grew similarly to CDXS’s over the last 12 months.

CSLLY's P/E Growth Rating (75) in the null industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that CSLLY’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSCSLLY
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
57%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
52%
Declines
ODDS (%)
Bearish Trend 13 days ago
84%
Bearish Trend 11 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
38%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSLLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CBAIX45.850.08
+0.17%
Calvert Balanced I
UIVMX12.01N/A
N/A
MFS Intrinsic Value R1
VSIEX21.94-0.01
-0.05%
JPMorgan International Equity I
MIQPX11.54-0.02
-0.17%
Morgan Stanley Inst International Eq R6
MCGRX17.49-0.07
-0.40%
BlackRock Natural Resources Inv C

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-2.13%
DNLI - CDXS
50%
Loosely correlated
-2.22%
BEAM - CDXS
48%
Loosely correlated
-3.00%
PRAX - CDXS
48%
Loosely correlated
+0.26%
ABCL - CDXS
46%
Loosely correlated
-0.98%
CRSP - CDXS
46%
Loosely correlated
-1.33%
More

CSLLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, CSLLY has been loosely correlated with ADPT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CSLLY jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSLLY
1D Price
Change %
CSLLY100%
-0.01%
ADPT - CSLLY
34%
Loosely correlated
+2.26%
RXRX - CSLLY
34%
Loosely correlated
-6.07%
VIR - CSLLY
33%
Poorly correlated
-4.82%
FOLD - CSLLY
33%
Poorly correlated
-2.25%
CDXS - CSLLY
33%
Poorly correlated
-2.13%
More